Efficacy and safety of Buxus sempervirens L. preparations (SPV(30)) in HIV-infected asymptomatic patients: a multicentre, randomized, double-blind, placebo-controlled trial

Autor: V. Rahelinirina, G. Gonzalez, J. Vandermander, Ph. Chantre, Ph. Halfon, Jacques Durant, Pierre Dellamonica, B. Rousse, S. Chamaret, L. Montagnier, D. Guedon
Rok vydání: 2012
Předmět:
Zdroj: Phytomedicine : international journal of phytotherapy and phytopharmacology. 5(1)
ISSN: 0944-7113
Popis: Summary The objective of the present study was to compare the efficacy and safety of two doses of SPV 30 in HIV asymptomatic patients. The study was designed as a randomized double-blind multicentre trial of two doses of SPV 30 (990 mg/d and 1980 mg/d) versus placebo. 145 previously untreated subjects with asymptomatic HIV infection (CDC group IV) and CD4 cell counts between 250 and 500 × 10 6 /1 were recruited. There was a statistically significant difference in therapeutic failures between groups in favor of SPV 30 990 mg including decreases of CD4 cell count 6 /1 and/or number of clinical aggravations (progression to AIDS or AIDS related complex). The treatment groups differed statistically in the rate of disease progression also in favor of SPV 30 990 mg/d. Fewer patients receiving SPV 30 990 mg/d had at the end an increase of viral load greater than 0.5 log ( P = 0.029). No severe side-effects were reported in the 3 groups. From these results we conclude that SPV 30 990 mg/d has beneficial effects in HIV asymptomatic patients and appears to delay the progression of HIV disease.
Databáze: OpenAIRE